Table 3.

Incidence and prevalence of venous thromboembolism in the outpatient population.

Author	Design	Population	Thromboprophylaxis during Hospitalization	Post discharge Thromboprophylaxis	Indication for VTE Detection	N	D-Dimer, ng/mL	Follow-up
Engelen[57]	Prospective	COVID-19 patients post discharge	prophylactic or intermediate dose of LMWH (no description of dosages)	8% received prophylactic LMWH post discharge	Screening US for all patients CTPA or VQ screening for ICU patients or those with D-dimer ≥ 2 μg/mL	102	590	6 weeks post-hospital discharge
Patell[59]	Retrospective	Discharged patients with confirmed COVID-19	NR	13 patients received prophylactic dose anticoagulation (10 LMWH, 2 DOACs, 1 UFH); they were excluded from the analysis	VTE diagnosis based on clinical suspicion	163		30 days
Roberts[58]	Retrospective	COVID-19 patients post-discharge	Thromboprophylaxis during admission to all Weight based dosing (<50 kg: enoxaparin 20 mg OD or 5000 units BID, 50–100 kg: 40 mg OD or 5000 units BID, 101–150 kg: 40 mg BID or 80 mg OD or UFH 5000 units TID, >150 kg: 60 mg BID or 120 mg OD or 5000 units TID)	None	Testing for VTE was only done in symptomatic patients	1877	NR	6 weeks post-hospital discharge
Rashidi[60]	Prospective	Discharged patients with suspected or confirmed COVID-19	1490 (97%) received VTE prophylaxis (enoxaparin 40–60 mg/daily, UFH 5000 IU/QID)	None	VTE diagnosis based on clinical suspicion	1529	NR	45–55 days
Giannis[61]	Prospective	Discharged patients with confirmed COVID-19	82% of patients received VTE prophylaxis	12.7% received extended VTE prophylaxis with DOAC or LMWH (enoxaparin 40 mg SQ daily) for 30 days in patients with an IMPROVE VTE score of ≥ 4 or D-dimer ≥ 2X ULN.	VTE diagnosis based on clinical suspicion	4906	340 ± 710	Up to 90 days post-discharge
Eswaran[62]	Retrospective	Discharged patients with confirmed COVID-19	NR	190 (42.5%) patients were discharged on VTE prophylaxis.	VTE diagnosis based on clinical suspicion	447		30 days post-discharge